Earnings summaries and quarterly performance for Janux Therapeutics.
Executive leadership at Janux Therapeutics.
Board of directors at Janux Therapeutics.
Research analysts covering Janux Therapeutics.
Recent press releases and 8-K filings for JANX.
Janux Therapeutics Announces Collaboration with Bristol Myers Squibb
JANX
New Projects/Investments
Revenue Acceleration/Inflection
- Janux Therapeutics, Inc. (JANX) entered into an exclusive worldwide license and collaboration agreement with Bristol Myers Squibb (BMS) on January 21, 2026.
- The agreement is for the development and commercialization of an undisclosed, novel, tumor-activated therapeutic targeting a validated solid tumor antigen.
- Janux will receive an upfront payment of $15 million and is eligible for up to $785 million in additional milestone payments, which includes a $35 million near-term milestone, bringing the total potential payments (upfront + all milestones) to approximately $800 million.
- Janux is also entitled to tiered royalties on global product sales, ranging from high-single digit to low-double digit percentages.
- Janux will conduct preclinical development up to IND submission, after which BMS will be responsible for subsequent development and global commercialization.
Jan 22, 2026, 9:30 PM
Janux Therapeutics Licenses Oncology Therapeutic to Bristol Myers Squibb
JANX
New Projects/Investments
Revenue Acceleration/Inflection
- Janux Therapeutics has entered into an exclusive worldwide licensing deal with Bristol Myers Squibb (BMS) for a novel "tumor-activated" therapeutic targeting an undisclosed antigen across multiple solid tumors.
- Under the agreement, Janux is eligible to receive $50 million in upfront and near-term payments, plus up to $800 million in development, regulatory, and commercial milestones, with potential total payments of approximately $850 million, in addition to tiered royalties.
- The collaboration involves Janux completing preclinical work through an IND, after which BMS will assume the IND, clinical development, and global commercialization, with Janux supporting the first Phase I study.
- This agreement is viewed by analysts as validation of Janux's differentiated tumor-activated platforms, which are designed to reduce off-tumor toxicity and enable more effective T-cell engager dosing in solid tumors.
Jan 22, 2026, 8:44 PM
Janux Therapeutics Announces Collaboration with Bristol Myers Squibb
JANX
New Projects/Investments
- Janux Therapeutics has entered into a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop an undisclosed, novel, tumor-activated therapeutic for solid tumors.
- Under the terms of the agreement, Janux is eligible to receive up to $50 million in upfront and near-term milestone payments, and up to approximately $800 million in aggregate development, regulatory, and commercial milestones, in addition to tiered royalties on global product sales.
- Janux will complete preclinical development up to IND submission, with Bristol Myers Squibb then taking responsibility for subsequent development and global commercialization, while Janux supports through the first Phase 1 clinical study.
Jan 22, 2026, 12:00 PM
Janux Therapeutics Provides Update on JANX007 Clinical Data and Strategy
JANX
New Projects/Investments
- JANX007 demonstrated a median radiographic progression-free survival (RPFS) of 7.9 months (QW) and 8.9 months (Q2W), alongside early and deep PSA reductions.
- A new CRS mitigation protocol (CRS P2) resulted in primarily grade 1 CRS with resolution typically within 24 hours, supporting potential outpatient treatment. The company is prioritizing 6 mg and 9 mg target doses and a patient-friendly Q2W dosing schedule, which reduced grade 3 adverse events from 35% to 21%.
- Janux Therapeutics is strategically focusing on taxane-naive, pre-Pluvicto MCRPC patients and exploring the PARP inhibitor refractory patient population, a market estimated at over $500 million and growing, which may offer an expedited approval pathway.
- The company highlights that T-cell engagers, like JANX007, may show an outsized improvement in overall survival relative to RPFS, a key factor for prostate cancer approvals, with low tumor burden patients showing an improved RPFS of 10.5 months.
Dec 1, 2025, 9:30 PM
Janux Provides Interim Clinical Data for JANX007 Program
JANX
New Projects/Investments
Guidance Update
- Janux presented interim Phase 1 clinical data for JANX007, a first-in-class, tumor-activated T-cell engager targeting PSMA for prostate cancer.
- The data showed durable responses and a median radiographic progression-free survival (RPFS) of 7.9 months in an expanded group of 29 patients, with a manageable safety profile.
- An every-other-week (Q2W) dosing schedule demonstrated an RPFS of 8.9 months in 19 evaluable patients and is supported for future development.
- JANX007 showed improved efficacy in lower tumor burden patients, guiding the company's focus on early-line taxane-naive patient populations.
- The company estimates the market size for PARP inhibitor refractory prostate cancer, a potential expedited approval path, to be over $500 million and growing.
Dec 1, 2025, 9:30 PM
Janux Therapeutics Reports Positive Data for JANX007 in MCRPC Patients
JANX
New Projects/Investments
Guidance Update
- Janux Therapeutics has dosed over 100 patients in its phase Ia study for JANX007, reporting a median radiographic progression-free survival (RPFS) of 7.3 months for all subjects and 7.9 months for an expanded group of 29 patients.
- The company's JANX007 program shows a maintained RPFS of 8.9 months for patients on an every-other-week (Q2W) dosing schedule, which also demonstrated a reduction in grade 3 adverse event profiles from 35% to 21% compared to once-weekly dosing, supporting a patient-friendly Q2W schedule.
- Early phase Ib data in taxane-naive patients demonstrated rapid and deep PSA reductions with primarily grade 1 Cytokine Release Syndrome (CRS), suggesting potential for an outpatient treatment setting and an improved RPFS of 10.5 months in low tumor burden patients.
- Janux Therapeutics is prioritizing 6 mg and 9 mg target doses and focusing on taxane-naive pre-Pluvicto MCRPC patients and PARP inhibitor refractory patients, with the latter market estimated at over $500 million and growing.
Dec 1, 2025, 9:30 PM
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
JANX
Earnings
New Projects/Investments
- Janux Therapeutics reported $989.0 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
- For the third quarter ended September 30, 2025, the company incurred $34.6 million in research and development expenses and $10.6 million in general and administrative expenses, resulting in a net loss of $24.3 million.
- Enrollment is ongoing for the JANX007 and JANX008 clinical trials, with updates expected in the fourth quarter of 2025.
Nov 6, 2025, 9:10 PM
Fintool News
In-depth analysis and coverage of Janux Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more